Maxim Group initiated coverage on Nuvectis Pharma with a new price target
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | $17.00 | Buy | Maxim Group |
| 3/17/2025 | $19.00 | Buy | Laidlaw |
| 7/13/2022 | $21.00 | Buy | Ladenburg Thalmann |
| 3/2/2022 | $14.00 | Buy | HC Wainwright & Co. |
Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00
Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00
Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
10-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "2025 was an eventful year for Nuvectis, with significant progress made in the NXP900 development program, laying the groundwork for multiple potential data readouts in 2026. Our Phase 1b monotherapy s
Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is a potent inhibitor of the SRC and YES1kinases. The brand name for Osimertinib is Tagrisso®, marketed by Astra Zeneca. Tagrisso, a 3rd generation EGFR inhibitor is broadly used in patients with NSCLCmut+ as single agent or in combination with chemotherapy a
Fort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT, the "Company")), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, including the combination with osimertinib in non-small cell lung cancer. To register for the event, click here. The event will feature Alexander Spira, MD, PhD, FACP, FASCO (Chief Scientific Officer, NEXT Oncology) and Asier Unc
Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, acquired by Johnson & Johnson in April 2025 for $14.6 billion. Ron Bentsur, Chairman and Chief Executive Officer of Nuvec
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of